Darlifarnib Combo Shows Activity in Resistant Kidney Cancer

A combination of darlifarnib (KO-2806) and Cabometyx (cabozantinib) has shown promising early activity in patients with advanced kidney cancer whose disease had already progressed on prior treatment. New data from an ongoing clinical trial suggest that this approach may help overcome resistance to therapy, a major challenge for patients with advanced disease.

Findings from a subset of patients in the phase 1 FIT-001 trial demonstrated meaningful tumor responses and disease control in individuals with clear cell renal cell carcinoma (ccRCC) who had previously been treated with Cabometyx. This is notable because patients whose cancer progresses on this therapy typically have limited treatment options and are less likely to respond to additional treatment with the same drug.

Darlifarnib plus Cabometyx shows tumor response in RCC

Among 16 patients included in the analysis, the combination therapy achieved an objective response rate of 44%, meaning nearly half of patients experienced measurable tumor shrinkage.

Additionally, the disease control rate — which includes patients whose cancer shrank or remained stable — reached 94%, suggesting that the majority of patients derived some clinical benefit from the treatment.

Tumor shrinkage was observed in approximately 75% of patients, with reductions ranging from 32% to 47% among those who responded.

Importantly, responses were seen even in heavily pretreated patients, including those whose best outcome with prior Cabometyx therapy had only been stable disease.

Treatment duration ranged from 8 weeks to as long as 56 weeks, with approximately one-third of patients still receiving therapy at the time of data cutoff.

A new approach in kidney cancer treatment

One of the most significant aspects of these findings is the potential ability of darlifarnib to overcome resistance to prior therapy.

Cabometyx is a commonly used treatment for advanced kidney cancer, but many patients eventually experience disease progression. After this occurs, subsequent treatment options are limited, and responses are often modest.

Darlifarnib is an investigational next-generation farnesyl transferase inhibitor designed to interfere with cellular pathways that help cancer cells survive and resist treatment. By combining it with Cabometyx, researchers aim to enhance the effectiveness of VEGF-targeted therapies and potentially restore sensitivity to treatment.

Early findings suggest that this strategy may help “re-sensitize” tumors, allowing patients to benefit again from therapies that had previously stopped working.

Unmet needs in advanced RCC

Clear cell renal cell carcinoma is the most common type of kidney cancer. Although advances in targeted therapy and immunotherapy have improved outcomes, many patients with advanced disease eventually develop resistance to treatment.

Cabometyx, a VEGF tyrosine kinase inhibitor, is widely used in this setting. However, once the disease progresses on this therapy, treatment options become more limited, and outcomes tend to worsen.

The development of combination approaches that can overcome resistance is a major focus of current research. Therapies like darlifarnib are designed to target key pathways involved in tumor growth and survival, with the goal of improving responses when used alongside existing treatments.

The findings come from the ongoing FIT-001 trial, a phase 1a/b study evaluating darlifarnib both as a single agent and in combination with other therapies, including Cabometyx.

In this subset analysis, researchers focused on patients with clear cell renal cell carcinoma who had previously received Cabometyx. All patients had also received prior immunotherapy, reflecting a population with advanced and heavily treated disease.

Patients received darlifarnib at varying dose levels in combination with standard doses of Cabometyx. The study is currently in the phase 1b expansion stage, which aims to further evaluate safety and determine the optimal dosing strategy for the combination.

Heavily pretreated RCC

The analysis included 16 patients with advanced clear cell renal cell carcinoma who had previously been treated with Cabometyx. This group represents a particularly challenging population, as these patients often have limited remaining treatment options.

Many participants had received multiple prior therapies, and some had only achieved stable disease with earlier treatments. Despite this, the combination therapy demonstrated meaningful activity across the group.

This suggests that the approach may be effective even in patients whose cancer has become resistant to standard therapies.

Durable responses and manageable safety

In addition to tumor response, the combination of darlifarnib and Cabometyx demonstrated a manageable safety and tolerability profile across multiple dose levels.

Durability of response is another encouraging aspect of the findings. Some patients remained on treatment for extended periods, with responses lasting up to 56 weeks.

These results were presented at the 2026 International Kidney Cancer Symposium in Europe and build on earlier data suggesting that darlifarnib may enhance the activity of targeted therapies across multiple cancer types.

Although these findings are preliminary and based on a small group of patients, they provide an important signal that this combination strategy may help address a significant unmet need in kidney cancer treatment.

Editor's note: This article is for informational purposes only and is not a substitute for professional medical advice, as your own experience will be unique. Use this article to guide discussions with your oncologist. Content was generated with AI, reviewed by a human editor, but not independently verified by a medical professional.

References

1. “Kura Oncology reports darlifarnib plus cabozantinib demonstrates robust activity in patients with clear cell renal cell carcinoma previously treated with cabozantinib,” by Kura Oncology. News Release; April 17, 2026.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.